153Sm-DOTMP (153Sm-CycloSAM™) is a bone pain palliation agent under development. Original patents are dated from 1989. This product must be considered as a generic drug. 153Sm-DOTMP is a tetraphosphonate molecule radiolabeled with 153Sm that localizes to bone surfaces in the same way as 153Sm-EDTMP (Quadramet®). There is only a small structural difference with Quadramet®.
153Sm-DOTMP did not go further than the early clinical stage and is probably on hold, like 166Ho-DOTMP. 166Ho-DOTMP went through many more clinical trials between 1999 and 2004 but did not convince further investors.
Leading Emitter: beta electrons (β–)